Table 3 |
|||
|
Between-group differences for DECTIN-1 Y238X genotype in joint-damage progression |
|||
|
Parameter |
Estimate |
SE |
P value |
|
|
|||
|
Intercept |
3.32 |
0.32 |
< 0.0001 |
|
DECTIN-1 genotype |
0.05 |
0.79 |
0.95 |
|
Intercept |
1.07 |
0.58 |
0.065 |
|
DECTIN-1 genotype |
-0.40 |
0.71 |
0.57 |
|
Joint damage at baseline |
2.65 |
0.53 |
< 0.0001 |
|
Rheumatoid factor + |
1.28 |
0.63 |
0.043 |
|
Average DAS28a |
1.26 |
0.24 |
< 0.0001 |
|
|
|||
|
DAS28: Disease Activity Score using 28 joint counts. Results of the linear regression model with 262 RA patients. The upper model tests the difference in annual joint-damage progression rate between wild-type patients and patients heterozygous for the DECTIN-1 Y238X polymorphism, indicated by the estimate of DECTIN-1 genotype (P = 0.95). The lower model tests the same (P = 0.57), with addition of baseline joint damage, rheumatoid factor positivity, and the time-averaged DAS28 as confounders. aTime-averaged DAS28 was centered. |
|||
|
Plantinga et al. Arthritis Research & Therapy 2010 12:R26 doi:10.1186/ar2933 |
|||
